Hide metadata

dc.date.accessioned2015-04-10T13:02:54Z
dc.date.available2015-04-10T13:02:54Z
dc.date.created2015-03-31T15:25:34Z
dc.date.issued2015
dc.identifier.citationSaatcioglu, Fahri . STAMP2 increases oxidative stress and is critical for prostate cancer. EMBO Molecular Medicine. 2015
dc.identifier.urihttp://hdl.handle.net/10852/43543
dc.description.abstractThe six transmembrane protein of prostate 2 (STAMP2) is an androgen‐regulated gene whose mRNA expression is increased in prostate cancer (PCa). Here, we show that STAMP2 protein expression is increased in human PCa compared with benign prostate that is also correlated with tumor grade and treatment response. We also show that STAMP2 significantly increased reactive oxygen species (ROS) in PCa cells through its iron reductase activity which also depleted NADPH levels. Knockdown of STAMP2 expression in PCa cells inhibited proliferation, colony formation, and anchorage‐independent growth, and significantly increased apoptosis. Furthermore, STAMP2 effects were, at least in part, mediated by activating transcription factor 4 (ATF4), whose expression is regulated by ROS. Consistent with in vitro findings, silencing STAMP2 significantly inhibited PCa xenograft growth in mice. Finally, therapeutic silencing of STAMP2 by systemically administered nanoliposomal siRNA profoundly inhibited tumor growth in two established preclinical PCa models in mice. These data suggest that STAMP2 is required for PCa progression and thus may serve as a novel therapeutic target.en_US
dc.languageEN
dc.language.isoenen_US
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleSTAMP2 increases oxidative stress and is critical for prostate canceren_US
dc.typeJournal articleen_US
dc.creator.authorJin, Yang
dc.creator.authorWang, Ling
dc.creator.authorQu, Su
dc.creator.authorSheng, Xia
dc.creator.authorKristian, Alexandr
dc.creator.authorMælandsmo, Gunhild M.
dc.creator.authorPällmann, Nora
dc.creator.authorYuca, Erkan
dc.creator.authorTekedereli, Ibrahim
dc.creator.authorGorgulu, Kivanc
dc.creator.authorAlpay, Neslihan
dc.creator.authorSood, Anil
dc.creator.authorLopez-Berestein, Gabriel
dc.creator.authorFazli, Ladan
dc.creator.authorRennie, Paul
dc.creator.authorRisberg, Bjørn
dc.creator.authorWæhre, Håkon
dc.creator.authorDanielsen, Håvard E.
dc.creator.authorOzpolat, Bulent
dc.creator.authorSaatcioglu, Fahri
cristin.unitcode185,15,29,40
cristin.unitnameSeksjon for biokjemi og molekylærbiologi
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1235384
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=EMBO Molecular Medicine&rft.volume=&rft.spage=&rft.date=2015
dc.identifier.jtitleEMBO Molecular Medicine
dc.identifier.volume7
dc.identifier.issue3
dc.identifier.startpage315
dc.identifier.endpage331
dc.identifier.doihttp://dx.doi.org/10.15252/emmm.201404181
dc.identifier.urnURN:NBN:no-47909
dc.type.documentTidsskriftartikkelen_US
dc.type.peerreviewedPeer reviewed
dc.source.issn1757-4676
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/43543/2/Jin%2Bet%2Bal.EMBO%2BMol%2BMed%2B2015.pdf
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International